Clinical Trial Update: Expanded Access Program for Revumenib

View source ↗

Summary

The expanded access program for Revumenib has been terminated and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Relapsed/Refractory Acute Leukemia | Status: NO_LONGER_AVAILABLE